Trial Profile
Effects of PH3 in Diabetic Nephropathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs PHN 031 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Therapeutic Use
- 03 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 25 Nov 2013 Planned end date changed from 1 Sep 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 25 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.